Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome

Summary

This Study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary therapeutic efficacy of oral administrations of CDZ173 in patients with primary Sjögren's syndrome.

Timeline

Start

2016-06-01

Primary completion

2017-05-17

Completion

2017-05-17

Outcome

Missed primary endpoint

registry analysis (superiority test); CDZ173 vs Placebo; Mean Difference (Net) -0.69 (95% CI -3.343 to 1.937) NCT02775916 ↗

Drugs

Indications